153 related articles for article (PubMed ID: 31736352)
1. Inhibition of tyrosine kinase receptor signaling attenuates fibrogenesis in an ex vivo model of human renal fibrosis.
Bigaeva E; Stribos EGD; Mutsaers HAM; Piersma B; Leliveld AM; de Jong IJ; Bank RA; Seelen MA; van Goor H; Wollin L; Olinga P; Boersema M
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F117-F134. PubMed ID: 31736352
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Liu F; Wang L; Qi H; Wang J; Wang Y; Jiang W; Xu L; Liu N; Zhuang S
Clin Sci (Lond); 2017 Aug; 131(16):2125-2143. PubMed ID: 28646122
[TBL] [Abstract][Full Text] [Related]
3. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
5. Precision-cut kidney slices (PCKS) to study development of renal fibrosis and efficacy of drug targeting ex vivo.
Poosti F; Pham BT; Oosterhuis D; Poelstra K; van Goor H; Olinga P; Hillebrands JL
Dis Model Mech; 2015 Oct; 8(10):1227-36. PubMed ID: 26112172
[TBL] [Abstract][Full Text] [Related]
6. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Liu F; Bayliss G; Zhuang S
Clin Sci (Lond); 2019 Jun; 133(12):1309-1320. PubMed ID: 31217321
[TBL] [Abstract][Full Text] [Related]
7. Molecular validation of the precision-cut kidney slice (PCKS) model of renal fibrosis through assessment of TGF-β1-induced Smad and p38/ERK signaling.
Zhang S; Liu Q; Xiao J; Lei J; Liu Y; Xu H; Hong Z
Int Immunopharmacol; 2016 May; 34():32-36. PubMed ID: 26919280
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Precision-Cut Kidney Slices as an Ex Vivo Screening Platform for Therapeutics in Human Renal Fibrosis.
Bigaeva E; Puerta Cavanzo N; Stribos EGD; de Jong AJ; Biel C; Mutsaers HAM; Jensen MS; Nørregaard R; Leliveld AM; de Jong IJ; Hillebrands JL; van Goor H; Boersema M; Bank RA; Olinga P
Pharmaceutics; 2020 May; 12(5):. PubMed ID: 32443499
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
11. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
13. Activation of the prostaglandin E
Jensen MS; Mutsaers HAM; Tingskov SJ; Christensen M; Madsen MG; Olinga P; Kwon TH; Nørregaard R
Acta Physiol (Oxf); 2019 Sep; 227(1):e13291. PubMed ID: 31054202
[TBL] [Abstract][Full Text] [Related]
14. Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices.
Bigaeva E; Gore E; Mutsaers HAM; Oosterhuis D; Kim YO; Schuppan D; Bank RA; Boersema M; Olinga P
Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165582. PubMed ID: 31676376
[TBL] [Abstract][Full Text] [Related]
15. The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.
Koyama K; Goto H; Morizumi S; Kagawa K; Nishimura H; Sato S; Kawano H; Toyoda Y; Ogawa H; Homma S; Nishioka Y
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):478-487. PubMed ID: 30540913
[TBL] [Abstract][Full Text] [Related]
16. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
18. Renal fibrosis in precision-cut kidney slices.
Stribos EG; Hillebrands JL; Olinga P; Mutsaers HA
Eur J Pharmacol; 2016 Nov; 790():57-61. PubMed ID: 27375078
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization.
Zhou BY; Wang WB; Wu XL; Zhang WJ; Zhou GD; Gao Z; Liu W
Acta Pharmacol Sin; 2020 Sep; 41(9):1234-1245. PubMed ID: 32327724
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
